DK3154957T3 - Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser - Google Patents

Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser Download PDF

Info

Publication number
DK3154957T3
DK3154957T3 DK15714185.4T DK15714185T DK3154957T3 DK 3154957 T3 DK3154957 T3 DK 3154957T3 DK 15714185 T DK15714185 T DK 15714185T DK 3154957 T3 DK3154957 T3 DK 3154957T3
Authority
DK
Denmark
Prior art keywords
methyl
histonmethyl
honorable
transfer
transferases
Prior art date
Application number
DK15714185.4T
Other languages
Danish (da)
English (en)
Inventor
Ena Xabier Aguirre
Santamarina Julen Oyarzabal
Cardoso Felipe Prósper
Gracia Maria Obdulia Rabal
Madoz Juan Roberto Rodríguez
José Enériz Edurne San
Original Assignee
Fundacion Para La Investig Medica Aplicada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Para La Investig Medica Aplicada filed Critical Fundacion Para La Investig Medica Aplicada
Application granted granted Critical
Publication of DK3154957T3 publication Critical patent/DK3154957T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK15714185.4T 2014-06-16 2015-03-30 Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser DK3154957T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14382230 2014-06-16
PCT/EP2015/056860 WO2015192981A1 (en) 2014-06-16 2015-03-30 Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases

Publications (1)

Publication Number Publication Date
DK3154957T3 true DK3154957T3 (da) 2020-02-17

Family

ID=51136403

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15714185.4T DK3154957T3 (da) 2014-06-16 2015-03-30 Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser

Country Status (9)

Country Link
US (1) US9840500B2 (https=)
EP (1) EP3154957B1 (https=)
JP (1) JP6527534B2 (https=)
CN (1) CN106536509B (https=)
AU (1) AU2015276537B2 (https=)
CA (1) CA2987978C (https=)
DK (1) DK3154957T3 (https=)
ES (1) ES2769648T3 (https=)
WO (1) WO2015192981A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501904A (ja) * 2015-12-14 2019-01-24 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダFundacion Para La Investigasion Medica Aplicada Dnaメチルトランスフェラーゼの阻害剤としての2,4,6,7−四置換キノリン化合物
HUE064145T2 (hu) * 2016-04-15 2024-03-28 Epizyme Inc Amin-szubsztituált aril- vagy heteroaril vegyületek, mint EHMT1 és EHMT2 inhibitorok
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
WO2017201199A1 (en) * 2016-05-17 2017-11-23 Duke University Compositions and methods for the treatment of prader-willi syndrome
WO2018049000A1 (en) * 2016-09-08 2018-03-15 The General Hospital Corporation Treatment of cancers having alterations within the swi/snf chromatin remodeling complex
WO2018119065A1 (en) 2016-12-22 2018-06-28 Asddr, Llc Use of histone methyltransferase inhibitors and histone deacetylase inhibitors for therapy of phelan-mcdermid syndrome
WO2018119208A1 (en) * 2016-12-22 2018-06-28 Global Blood Therapeutics, Inc. Histone methyltransferase inhibitors
EP3600318A4 (en) * 2017-03-31 2021-06-09 Epizyme, Inc. METHOD OF USING EHMT2 INHIBITORS
CN110621316B (zh) 2017-04-21 2024-01-26 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
WO2018226998A1 (en) 2017-06-09 2018-12-13 Global Blood Therapeutics, Inc. Azaindole compounds as histone methyltransferase inhibitors
WO2018229139A1 (en) 2017-06-14 2018-12-20 Fundación Para La Investigación Médica Aplicada Novel compounds for use in cancer
WO2019036384A1 (en) 2017-08-15 2019-02-21 Global Blood Therapeutics, Inc. TRICYCLIC COMPOUNDS AS HISTONE INHIBITORS METHYLTRANSFERASES
WO2019036377A1 (en) 2017-08-15 2019-02-21 Global Blood Therapeutics, Inc. TRICYCLIC COMPOUNDS AS HISTONE INHIBITORS METHYLTRANSFERASES
CA3079273A1 (en) * 2017-10-18 2019-04-25 Epizyme, Inc. Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof
IL273824B2 (en) * 2017-10-18 2024-07-01 Epizyme Inc Methods for using EHMT2 inhibitors in the treatment or prevention of blood disorders
WO2019229765A1 (en) * 2018-05-29 2019-12-05 Council Of Scientific & Industrial Research, India Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof
WO2019243236A1 (en) 2018-06-18 2019-12-26 Fundación Para La Investigación Médica Aplicada New anticancer drug combinations
CN112390791B (zh) * 2019-08-14 2023-08-01 复旦大学 一类dna甲基转移酶1荧光探针及其用途
CA3189027A1 (en) 2020-07-11 2022-01-20 Pfizer Inc. Antiviral heteroaryl ketone derivatives
CA3188260A1 (en) * 2020-08-07 2022-02-10 Dimitrios Iliopoulos Small molecules for the treatment of autoimmune diseases and cancer
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN115160294B (zh) * 2022-06-27 2023-09-29 中山大学 一种G9a/GLP共价抑制剂及其制备方法及应用
CN120965666B (zh) * 2025-10-21 2026-02-17 四川大学华西医院 一种喹啉类化合物、制备方法和用途及其药物组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221882B1 (en) * 1997-07-03 2001-04-24 University Of Iowa Research Foundation Methods for inhibiting immunostimulatory DNA associated responses
US6479504B1 (en) * 1999-06-16 2002-11-12 The University Of Iowa Research Foundation Antagonism of immunostimulatory CpG-oligonucleotides by 4-aminoquinolines and other weak bases
US6440995B1 (en) * 1999-10-01 2002-08-27 Hoffman-La Roche Inc. Quinolin-4-yl derivatives
DK1088818T3 (da) * 1999-10-01 2005-03-14 Hoffmann La Roche Quinolin-4-yl-derivater
AU2002361846A1 (en) 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
CA2513086A1 (en) 2002-12-19 2004-07-08 Scios Inc. Treatment of obesity and associated conditions with tgf-.beta. inhibitors
WO2004112710A2 (en) * 2003-06-17 2004-12-29 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß
EP2174938A1 (en) * 2006-10-12 2010-04-14 SuperGen, Inc. Quinoline derivatives for modulating DNA methylation
CN101535295A (zh) * 2006-10-12 2009-09-16 休普基因公司 用于调节dna甲基化的喹啉衍生物
US7790746B2 (en) * 2007-10-12 2010-09-07 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
CN102625799A (zh) * 2009-06-25 2012-08-01 安姆根有限公司 杂环化合物及其用途
CN102597218B (zh) * 2009-08-12 2017-10-27 国立大学法人京都大学 用于诱导多能干细胞分化成神经前体细胞的方法
CN102596200A (zh) * 2009-11-07 2012-07-18 默克专利有限公司 作为TGF-β受体激酶抑制剂的杂芳基氨基喹啉类
JP2014530910A (ja) * 2011-10-24 2014-11-20 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッドGlaxosmithkline Intellectual Property No.2 Limited 新規化合物
EP2828250B1 (en) * 2012-03-19 2021-03-10 Imperial College Innovations Limited Quinazoline compounds and their use in therapy
EP2730558A1 (en) 2012-11-08 2014-05-14 Ikerchem, S.L. Indole derivatives, pharmaceutical compositions containing such indoles and their use as DNA methylation modulators
EP2918014B1 (en) * 2012-11-09 2018-10-31 OCT Circuit Technologies International Limited Analog to digital conversion method with offset tracking and correction and analog to digital converter implementing the same
JP6338601B2 (ja) * 2013-03-01 2018-06-06 フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ ホスホジエステラーゼとヒストンデアセチラーゼの二重阻害剤としての新規な化合物

Also Published As

Publication number Publication date
ES2769648T3 (es) 2020-06-26
US20170121316A1 (en) 2017-05-04
CN106536509A (zh) 2017-03-22
EP3154957A1 (en) 2017-04-19
CA2987978A1 (en) 2015-12-23
JP6527534B2 (ja) 2019-06-05
US9840500B2 (en) 2017-12-12
JP2017524668A (ja) 2017-08-31
EP3154957B1 (en) 2019-11-20
AU2015276537B2 (en) 2019-03-14
CN106536509B (zh) 2020-06-09
AU2015276537A1 (en) 2017-01-05
WO2015192981A1 (en) 2015-12-23
CA2987978C (en) 2022-08-16

Similar Documents

Publication Publication Date Title
DK3154957T3 (da) Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser
IL263586B (en) Inhibitors of the menin-mll interaction
DK3119772T3 (da) Heteroaryl syk-hæmmere
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
IL248410A0 (en) A system for the closed transfer of liquids
DK3158054T3 (da) Genetisk modificerede bakterier og fremgangsmåder til genetisk modifikation af bakterier
DK3536685T3 (da) Bicyklisk-fusionerede heteroaryl- eller arylforbindelser og anvendelse deraf som irak4 inhibitorer
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3207043T6 (da) Dihydropyrrolopyridin-inhibitorer af ror-gamma
LT3303334T (lt) Tirozinkinazės inhibitoriai
HRP20190407T1 (hr) Heteroarilni spojevi za inhibiciju kinaza
DK3718507T3 (da) Anordninger til behandling af nedre ekstremitetsvaskulatur
DK3183260T3 (da) Modificerede oligonukleotider og fremgangsmåder til deres syntese
EP4096138C0 (en) DATA TRANSMISSION METHODS
HRP20181899T1 (hr) Biaril inhibitori kinaze
DK3371165T3 (da) Btk-inhibitor til anvendelse til behandling af kræft
DK3313833T3 (da) Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase
DK3157929T3 (da) Pyrazolforbindelser som modulatorer af fshr og anvendelser deraf
DK3341379T3 (da) EZH2-hæmmere
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3481819T3 (da) Forbindelser og anvendelse deraf til reducering af urisyreniveauer
DK3215493T3 (da) Syntese af copanlisib og dihydrochloridsalt deraf
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
EP3200745C0 (en) LIQUID TRANSFER SYSTEM